映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

已收盘 05-08 16:08:16

201.000

+0.000

0.00%

最高205.000	最低196.600	成交量22.06万
今开204.600	昨收201.000	日振幅4.18%
总市值171.73亿	流通市值171.73亿	总股本8,544万
成交额4,403万	换手率0.26%	流通股本8,544万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":201,"timestamp":1746691696020,"preClose":201,"halted":0,"volume":220600,"delay":0,"floatShares":85436500,"shares":85436464,"eps":-141.04634847220603,"marketStatus":"已收盘","change":0,"latestTime":"05-08 16:08:16","open":204.6,"high":205,"low":196.6,"amount":44026660,"amplitude":0.041791,"askPrice":201,"askSize":4000,"bidPrice":200,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-141.0463592141553,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746754200000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":201,"openAndCloseTimeList":[[1746667800000,1746676800000],[1746680400000,1746691200000]],"volumeRatio":0.604282,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2533913794","title":"CR率为99.1%的CAR-T，使近95%患者疾病未发生进展的ADC获IND进展，涉及上海医药、映恩生物等【CDE 一周动态】","url":"https://stock-news.laohu8.com/highlight/detail?id=2533913794","media":"医麦客","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533913794?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:01","pubTimestamp":1746666095,"startTime":"0","endTime":"0","summary":"，涉及企业包括上海医药、康爱生物、映恩生物等。IND 受理上海医药：B019CD19/CD22 CAR-T据公开资料显示，靶向 CD19 和 CD22 的嵌合抗原受体自体 T 细胞注射液是上海医药研发的双顺反子 CD19/CD22 CAR-T。此前，该抗体针对晚期或转移性实体瘤的 IND 申请已获得 CDE 临床默示许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508091742a6d6f7ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508091742a6d6f7ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09606","02607","BK1197"],"gpt_icon":0},{"id":"2533186626","title":"映恩生物-B(9606.HK)：核心产品快速推进 FIC管线迈向全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2533186626","media":"中信建投证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533186626?lang=zh_cn&edition=full","pubTime":"2025-05-08 00:00","pubTimestamp":1746633600,"startTime":"0","endTime":"0","summary":"核心平台DITAC 管线进展最快，截至目前已有5 项临床资产分别获得美国FDA 与中国药监局IND 批准，并在全球17 个国家的230 余家临床中心开展7 项MRCT，累计入组患者超过2000 人。同时，映恩生物已与多家国际领先药企建立战略合作，累计交易金额超过60 亿美元，全球化布局加速推进。2024 年全球ADC销售额近130 亿美元，ADC 市场快速扩大。B7-H3 是肿瘤免疫逃逸机制中的重要靶点， 治疗潜力广泛，目前尚无B7-H3 ADC 获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508193128a6d79fea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508193128a6d79fea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2533885647","title":"映恩生物配售260万股 预计获2.35亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533885647","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533885647?lang=zh_cn&edition=full","pubTime":"2025-05-07 12:47","pubTimestamp":1746593227,"startTime":"0","endTime":"0","summary":"映恩生物-B发布公告，公司于2025年5月6日悉数行使招股章程所述的超额配股权，涉及合共260万股股份，约占全球发售项下可供认购发售股份总数的15%。此次超额配发股份的发行价为每股94.6港元，预计将为公司带来约2.35亿港元的净额收入，扣除承销费用及佣金后，这笔资金将按招股章程所述的用途进行使用。经过此次超额配股权的行使，公司股东的持股比例也发生了变化，LAVUSD的持股比例由19.53%降至18.95%，而公众股东的持股比例则由72.86%增至73.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050712471497518464&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050712471497518464&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606","BK1161"],"gpt_icon":0},{"id":"2533163481","title":"映恩生物-B(09606)：悉数行使超额配股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2533163481","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533163481?lang=zh_cn&edition=full","pubTime":"2025-05-06 21:36","pubTimestamp":1746538574,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B(09606)发布公告，联席代表(为其本身及代表国际承销商)已于2025年5月6日悉数行使招股章程所述的超额配股权，涉及合共259.98万股股份，占全球发售项下可供认购发售股份总数的约15%(经计及发售量调整权已获悉数行使但于行使超额配股权之前)。超额配发股份将由公司按每股股份94.60港元发行及配发。超额配发股份将用于促成向 DualityBio Ltd.归还借股协议项下用于补足国际发售项下超额分配的259.98万股借入股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09606"],"gpt_icon":0},{"id":"2531089001","title":"映恩生物-B04月30日主力净流出148.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2531089001","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531089001?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000936,"startTime":"0","endTime":"0","summary":"04月30日, 映恩生物-B股价跌3.26%，报收207.40元，成交金额4990.5万元，换手率0.28%，振幅5.60%，量比0.38。映恩生物-B今日主力资金净流出148.3万元，上一交易日主力净流入885.1万元。该股近5个交易日下跌5.49%，主力资金累计净流入569.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出504.4万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170901a46d74ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170901a46d74ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":0},{"id":"1124349230","title":"异动解读 | 映恩生物-B盘中大涨5.01%，两项研究将在美国临床肿瘤学会年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1124349230","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124349230?lang=zh_cn&edition=full","pubTime":"2025-04-28 15:56","pubTimestamp":1745826981,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨5.01%，引发市场关注。截至发稿时，该股报216.6港元，成交额达1.49亿港元。消息面上，公司将在即将举行的2025年美国临床肿瘤学会年会上公布两项重要研究结果。ASCO年会将于5月30日至6月3日在美国芝加哥举行，相关研究摘要全文将于5月23日在ASCO官方网站发布。此外，国泰海通发布的最新研报也为映恩生物-B带来利好。这些积极因素共同推动了映恩生物-B股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"2530442210","title":"港股异动 | 映恩生物-B(09606)尾盘涨超4% 两项研究结果将在2025美国临床肿瘤学会年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2530442210","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530442210?lang=zh_cn&edition=full","pubTime":"2025-04-28 15:49","pubTimestamp":1745826580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B尾盘涨超4%，截至发稿，涨4.44%，报216.6港元，成交额1.49亿港元。消息面上，2025年美国临床肿瘤学会年会将于5月30日至6月3日在美国芝加哥举行。映恩生物将在以口头报告形式公布HER3 ADC DB-1310及B7H3 ADC DB-1311/BNT324的两项研究结果，相关研究摘要全文将于当地时间2025年5月23日发布在 ASCO 官方网站上。国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 映恩生物-B(09606)尾盘涨超4% 两项研究结果将在2025美国临床肿瘤学会年会公布","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"gpt_icon":0},{"id":"2530909349","title":"映恩生物-B04月25日遭主力抛售578万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530909349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530909349?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:17","pubTimestamp":1745569048,"startTime":"0","endTime":"0","summary":"04月25日, 映恩生物-B股价跌7.82%，报收207.40元，成交金额1.58亿元，换手率0.85%，振幅10.49%，量比0.63。映恩生物-B今日主力资金净流出578万元，连续3日净流出，上一交易日主力净流出67万元。该股近5个交易日上涨9.29%，主力资金累计净流出1470万元；近20日主力资金累计净流出1719万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425171123a46694b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425171123a46694b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2529269846","title":"映恩生物两项研究结果将在2025美国临床肿瘤学会年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2529269846","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529269846?lang=zh_cn&edition=full","pubTime":"2025-04-24 14:41","pubTimestamp":1745476868,"startTime":"0","endTime":"0","summary":"2025年美国临床肿瘤学会年会将于5月30日至6月3日在美国芝加哥举行。映恩生物将在以口头报告形式公布HER3 ADC DB-1310及B7H3 ADC DB-1311/BNT324的两项研究结果，相关研究摘要全文将于当地时间 2025年5月23日发布在 ASCO 官方网站上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424145928a464ecd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424145928a464ecd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2529532107","title":"映恩生物-B04月22日主力净流入272万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529532107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529532107?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:15","pubTimestamp":1745309744,"startTime":"0","endTime":"0","summary":"04月22日, 映恩生物-B股价涨9.80%，报收219.60元，成交金额2.91亿元，换手率1.54%，振幅14.50%，量比0.00。映恩生物-B今日主力资金净流入272万元，上一交易日主力净流出591万元。该股近5个交易日上涨131.71%，主力资金累计净流出568万元；近20日主力资金累计净流出568万元，其中净流出天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170825a6c38aad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170825a6c38aad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":0},{"id":"2529315118","title":"映恩生物-B午后涨超15% 国泰海通给予“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2529315118","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529315118?lang=zh_cn&edition=full","pubTime":"2025-04-22 13:22","pubTimestamp":1745299320,"startTime":"0","endTime":"0","summary":"　　映恩生物-B早盘涨超16%，高见234港元，创上市新高。午后上涨15.20%，现报230.80港元，成交额1.97亿港元。　　公开资料显示，映恩生物是全球抗体偶联药物领域的关键领跑者，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。　　国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。首次覆盖，给予“增持”评级。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzkuy0978708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606"],"gpt_icon":1},{"id":"1118159098","title":"异动解读 | 映恩生物-B盘中大涨15%，ADC新药研发引发市场热捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1118159098","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118159098?lang=zh_cn&edition=full","pubTime":"2025-04-22 12:46","pubTimestamp":1745297189,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨15.00%，股价一度触及232.8港元的历史新高，引发市场广泛关注。截至盘中，该股报226.4港元，成交额达1.75亿港元。映恩生物是全球抗体偶联药物领域的关键领跑者，专注于为癌症和自身免疫性疾病等患者研发ADC创新药物。国泰海通发布的最新研报进一步推动了映恩生物-B的股价上涨。该券商看好公司聚焦ADC新药研发的战略，以及产品达成的多项对外授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"1194208776","title":"异动解读 | 映恩生物-B盘中大涨15%，ADC新药研发进展及券商看好推动股价创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1194208776","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194208776?lang=zh_cn&edition=full","pubTime":"2025-04-22 12:46","pubTimestamp":1745297189,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨15%，股价一度触及232.8港元，创上市以来新高。截至11时52分，该股涨幅收窄至15%，报230.2港元，成交额超1.75亿港元。国泰海通证券近期发布研报，给予映恩生物-B\"增持\"评级，目标价300.70港元。此外，映恩生物产品管线丰富，ADC布局持续扩容，预计2025-2027年收入将稳步增长。券商的积极评级进一步提振了投资者信心，推动股价创下新高。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"gpt_icon":0},{"id":"2529318988","title":"港股异动 | 映恩生物-B(09606)涨超16%创新高 公司聚焦ADC新药研发 核心产品初步展现治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2529318988","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529318988?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:58","pubTimestamp":1745294280,"startTime":"0","endTime":"0","summary":"映恩生物-B午前涨超16%，高见232.8港元，创上市新高。截至发稿，涨13.2%，报226.4港元，成交额1.75亿港元。公开资料显示，映恩生物是全球抗体偶联药物领域的关键领跑者，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。公司拥有自主研发的两款核心产品，此外，公司有五项处于临床阶段的资产已获得美国食品药品管理局及中国国家药品监督管理局的研究用新药批准。国泰海通发布研报称，公司聚焦ADC新药研发，产品达成多项License-out对外授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzepc5545457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ADC","BK4231","BK4080","09606"],"gpt_icon":1},{"id":"2529844691","title":"国泰海通：首予映恩生物-B(09606)“增持”评级 目标价300.70港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529844691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529844691?lang=zh_cn&edition=full","pubTime":"2025-04-21 14:25","pubTimestamp":1745216757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B，给予“增持”评级。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先跟进。HER2ADC已成为HER2+BC等领域的重要治疗手段，Enhertu在临床持续取得突破，正在引领临床用药迭代。风险调整后预计国内峰值有望达26亿元、美国峰值有望达16亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"gpt_icon":1},{"id":"2527534280","title":"创下2022年以来18A融资规模新纪录，ADC独角兽映恩生物-B(09606)强势登陆港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527534280","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527534280?lang=zh_cn&edition=full","pubTime":"2025-04-16 12:09","pubTimestamp":1744776596,"startTime":"0","endTime":"0","summary":"坐拥自2022年以来18A生物科技板块内最大融资规模，暂居2025年港股IPO首日涨幅榜榜首......映恩生物-B凭借上述成绩，完成了从“国内ADC黑马”向“港股18A明星标的”的华丽转身。自2023年以来，映恩生物先后与BioNTech、百济神州、Adcendo、GSK、Avenzo、三生制药等国内外顶尖药企达成多项BD交易，总价值超60亿美元，助力公司成为国产ADC独角兽与出海“生力军”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4080","YANG","BK4231","09606","ADC","HSTECH","BK4614"],"gpt_icon":1},{"id":"2527477255","title":"映恩生物登陆港交所首日大涨116.70%；百利天恒第10款ADC获批临床试验 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2527477255","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527477255?lang=zh_cn&edition=full","pubTime":"2025-04-16 07:40","pubTimestamp":1744760413,"startTime":"0","endTime":"0","summary":"NO.1映恩生物登陆港交所首日大涨116.70%4月15日，映恩生物正式在港交所挂牌，截至收盘股价大涨116.70%。公司本次IPO（首次公开发行）认购募资总额为2.1亿美元，约合人民币15.4亿元，刷新了2022年以来港股18A生物科技公司的融资纪录。资料显示，映恩生物成立于2019年，主要研发创新抗体偶联药物（ADC），用于治疗癌症、自身免疫性疾病等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504163377896945.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504163377896945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1161","BK4231","09606","ADC","BK1574","BK1583","03347","09939","BK1576","BK1141","BK4080"],"gpt_icon":1},{"id":"2527419593","title":"映恩生物港股上市首日收涨116.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419593","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527419593?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:57","pubTimestamp":1744721869,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）4月15日，映恩生物（09606.HK）登录港交所，上市首日收涨116.7%，收盘价为205港元/股，总市值为175.1亿港元。招股书显示，映恩生物是一家专注于抗体偶联药物（ADC）研发的全球领跑企业，聚焦癌症及自身免疫性疾病领域。公司依托自主研发的四大技术平台，构建了差异化显著的创新管线，涵盖12款自主研发的ADC候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377602771.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377602771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["YANG","BK4614","09606","HSTECH"],"gpt_icon":0},{"id":"2527419596","title":"映恩生物上市首日涨超110%，每手赚上万港元 董事会主席朱忠远：虽三四年未融资，但是公司现金越来越多","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419596","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527419596?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:46","pubTimestamp":1744721219,"startTime":"0","endTime":"0","summary":"4月15日，映恩生物-B（HK09606，股价205港元，市值175.1亿港元）在港交所挂牌上市，这是港交所2022年以来融资规模最大的“18A”生物科技上市公司（指适用港交所上市规则第18A章的公司）。映恩生物每股定价94.6港元，共发行1733.23万股。上市首日开盘后，映恩生物一路走高，盘中最高涨幅曾超过130%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377600285.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377600285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09606"],"gpt_icon":1},{"id":"2527195974","title":"映恩生物首日暴涨116%：从“破发潮”到大涨，港股18A企业现反转信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2527195974","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527195974?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:44","pubTimestamp":1744721065,"startTime":"0","endTime":"0","summary":"尽管市场走势疲软，但ADC（抗体偶联药物）龙头企业映恩生物(09606.HK)上市首日仍然大涨。4月15日，映恩生物(09606.HK)在港交所主板挂牌上市，当天报收于205港元，首日涨幅超过116%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504153377599531.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504153377599531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09606","HSTECH","BK4614","YANG"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.0309},{"period":"1month","weight":1.1247},{"period":"ytd","weight":1.1247}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.1444},{"period":"3month","weight":0.0862},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.228},{"period":"ytd","weight":0.1312}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}